WaveMan
WaveMan · Company
TENX · Tenax Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

TENX Tenax Therapeutics (TENX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0000034956
Quote by TradingView
Cluster · 4 insidersC-suite buying · 2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
86
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $51.3K priced

What the filings say about TENX

Insiders, 180 days
+$6.4M net bought
4 buyers

Tenax Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, TENAX THERAPEUTICS, INC. insiders bought a net $6.4M of stock across 29 Form 4 purchases and sales, with 4 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
ADAR1 Capital Management, LLC
BUY
2026-10-21 SEC
331,979
$550.7K
-2.3%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Oct 20, 2026.
  • The trade is 4.5% of the 7,447,000 shares held after it.
  • No other insider bought within 30 days.
  • 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider ADAR1 Capital Management, LLC bought about $550.7K of TENX on Oct 21, 2026; 86 funds added in the latest 13F quarter.
ADAR1 Capital Management, LLC
BUY
2026-10-21 SECtraded 2026-10-20
254,342
$405.7K
-2.3%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 buys), the last on Oct 19, 2026.
  • The trade is 3.6% of the 7,115,021 shares held after it.
  • No other insider bought within 30 days.
  • 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider ADAR1 Capital Management, LLC bought about $405.7K of TENX on Oct 20, 2026; 86 funds added in the latest 13F quarter.
ADAR1 Capital Management, LLC
BUY
2026-10-21 SECtraded 2026-10-19
336,528
$507.0K
-2.3%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 buys), the last on Sep 3, 2026.
  • The trade is 4.9% of the 6,860,679 shares held after it.
  • No other insider bought within 30 days.
  • 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider ADAR1 Capital Management, LLC bought about $507.0K of TENX on Oct 19, 2026; 86 funds added in the latest 13F quarter.
Doogan Declan
Director
BUY
2026-09-17 SECtraded 2026-09-16
53,000
$101.8K
-9.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 95.9% of the 55,274 shares held after it.
  • 3 other insiders bought within 30 days.
  • 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Doogan Declan bought about $101.8K of TENX on Sep 16, 2026; 3 other insiders bought within 30 days and 86 funds added in the latest 13F quarter.
Giordano Christopher Thomas
CEO
BUY
2026-09-15 SEC
4,850
$8.8K
-5.5%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Sep 11, 2026.
  • +62.4% median (+65.0% mean) 90-day return after 3 previous buys.
  • The trade is 21.9% of the 22,174 shares held after it.
  • 3 other insiders bought within 30 days.
  • 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO Giordano Christopher Thomas bought about $8.8K of TENX on Sep 15, 2026; 3 other insiders bought within 30 days and 86 funds added in the latest 13F quarter.
29 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 24 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$6.4M over 180 days
+$6.4M over 90 days · +$6.3M of it by a 10%+ holder
more than 95% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
86 funds bought in last quarter
more than 63% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
24.1% of the float short (float per yahoo 2026-10-26) · 2.4 days to cover · settled 2026-09-30
more than 93% of Pharma & Biotech
The situation: each line is one rule over one dataset
4 insiders independently bought a net $6.4M while the stock fell 89% over six months, with no planned sales queued.
What changed in the last 30 days
Oct 21Insider ADAR1 Capital Management, LLC bought $1.5M (3 trades, Oct 19 to Oct 21)

Watch TENX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-76.5%12M
-81%-4%+73%+150%2025-102025-122026-022026-042026-062026-082026-10 2026-09-03 · ADAR1 Capital Management, LLC bought $1.6M2026-08-21 · ADAR1 Capital Management, LLC bought $1.3M2026-08-31 · ADAR1 Capital Management, LLC bought $722.6K2026-10-21 · ADAR1 Capital Management, LLC bought $550.7K2026-10-19 · ADAR1 Capital Management, LLC bought $507.0K2026-10-20 · ADAR1 Capital Management, LLC bought $405.7K2026-08-20 · ADAR1 Capital Management, LLC bought $359.5K2026-09-02 · ADAR1 Capital Management, LLC bought $337.6K2026-09-01 · ADAR1 Capital Management, LLC bought $321.6K2026-08-24 · ADAR1 Capital Management, LLC bought $188.4K2026-09-16 · Doogan Declan bought $101.8K2025-11-17 · MCGAULEY THOMAS bought $36.1K2025-12-09 · Rich Stuart bought $25.6K2025-12-08 · Rich Stuart bought $25.2K2025-12-04 · Rich Stuart bought $23.0K2025-11-17 · MCGAULEY THOMAS bought $14.7K2025-11-18 · Almenoff June Sherie bought $14.3K2025-12-03 · Rich Stuart bought $13.6K2025-11-18 · Giordano Christopher Thomas bought $12.5K2026-09-11 · Giordano Christopher Thomas bought $11.2K2026-09-11 · STAAB THOMAS R II bought $11.0K2025-12-02 · Rich Stuart bought $9.0K2026-09-15 · Giordano Christopher Thomas bought $8.8K2025-11-17 · MCGAULEY THOMAS bought $7.3K2025-11-20 · Giordano Christopher Thomas bought $4.1K2025-11-19 · Giordano Christopher Thomas bought $3.4K2025-11-17 · Almenoff June Sherie bought $6652026-03-10 · Christopher Thomas Giordano filed a 5%+ stake (6.79%)
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns TENX: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
3,942,373 sh
$57.4M
Vivo Capital, LLC
2,500,000 sh
$36.4M
BlackRock, Inc.
1,727,988 sh
$25.1M
PERCEPTIVE ADVISORS LLC
1,700,000 sh
$24.7M
Stonepine Capital Management, LLC
1,320,000 sh
$19.2M

Congress trades in TENX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Christopher Thomas Giordano
Activist 13D · 2026-03-10
6.79%

TENX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

TENX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Fund
$871.5K position · as of 2026-06-30
0.9%
Fidelity Advisor Biotechnology Fund
$6.1M position · as of 2026-07-31
0.3%
Fidelity Series Small Cap Core Fund
$3.9M position · as of 2026-07-31
0.2%
BNY Mellon Small/Mid Cap Growth Fund
$1.8M position · as of 2026-06-30
0.2%
Fidelity Series Small Cap Discovery Fund
$4.1M position · as of 2026-07-31
0.2%
Fidelity Small Cap Discovery Fund
$4.6M position · as of 2026-07-31
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 2
0 active
3
Phase 3
3 active
What changed recently
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
2026-10-16 · Recruiting → Active Not Recruiting
Phase 3
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$8.1M
$21.7M
$1.9M
-99%
n/a
2024
$7.4M
$7.7M
$1.7M
n/a
n/a
2023
$644.8K
$515.7K
$323.8K
-99%
n/a
2022
$667.3K
$652.0K
$344.9K
-89%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
4 insiders reported buying shares.
The record shows a net $6.4M bought by insiders over 180 days, 86 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

TENX financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$46.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-59.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-57.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-63.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-71.5%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$0$0n/an/a
Operating income-$56.4M-$19.5M-$8.2M$11.1M
Net income-$52.6M-$17.6M-$7.7M$11.0M
EPS (diluted)-1.34-1.15-31.04n/a
Operating cash flow-$35.8M-$14.8M-$5.9M-$11.4M
Cash$97.6M$94.9M$9.8M$2.1M
SEC XBRL, fiscal years, as known on 2026-10-28

TENX Stock Sonar score 4/7 axes

Find similar shapesCompare

TENX ranks highest on insider conviction (94th percentile) and institutional and government (63rd), and lowest on risk and compliance (39th), among Pharma & Biotech peers.

Profitability
43
Inputs
  • Return on equity-59.8% · 48 pct, sector of 545
  • Return on assets-57.0% · 40 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-63.3% · 40 pct, sector of 576
Insider conviction
94
Inputs
  • Net Form 4 buying (codes P and S), 180d$6.4M · 95 pct, sector of 428
  • Insider buyers, 180d4 · 94 pct, sector of 437
Institutional and government
63
Inputs
  • Funds adding, latest quarter86 · 63 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
39
Inputs
  • Short interest, % of float+24.1% · 9 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+7.2% · 70 pct, sector of 511
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

TENX filings, in plain words

Are Tenax Therapeutics insiders buying or selling TENX?

In the 180 days to 2026-10-28, Tenax Therapeutics insiders were net buyers, a net $6.4M across purchases and sales reported on Form 4, by 4 buyers.

Read the full summary

In the 180 days to 2026-10-28, Tenax Therapeutics insiders were net buyers of TENX, a net $6.4M across purchases and sales reported on Form 4 by 4 buyers. Most of that figure, $6.3M, came from a holder of 10% or more rather than an officer or director. 4 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. The latest 5% ownership filing is a 13D by Christopher Thomas Giordano, filed 2026-03-10, for 6.8% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies